作者:老萝卜头金斯瑞生物科技(01548.HK,下称“金斯瑞”)2024财年财报显示,净利润为29.62亿美元,同比大涨3202.19%,实现扭亏为盈。然而,金斯瑞这一亮眼数字的背后却暗藏玄机——32亿美元的一次性收益源于会计操作,即解除对子公司传奇生物(LEGN.NASDAQ)的合并报表。0132亿美元的真实底色金斯瑞这一操作的本质,是将传奇生物从并表子公司转为联营公司,其市值与账面净值的差额被...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.